Amplyx Pharmaceuticals

Amplyx Pharmaceuticals

Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

June 8, 2020

Amplyx Pharmaceuticals announces the appointment of Chris LeMasters to the position of chief operating officer and Carlos Sattler, M.D., as senior vice president, clinical development.

May 19, 2020

Amplyx Pharmaceuticals Closes $53M Series C Extension.

August 2017

Amplyx Pharmaceuticals raises a $67,000,000 series C round from RiverVest Venture Partners, Pappas Capital, Arix Bioscience plc, Lundbeckfonden Ventures, New Enterprise Associates, Sofinnova Partners and BioMed Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 8, 2020
BioSpace
Amplyx Pharmaceuticals , a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune syste
Christine Hall
May 19, 2020
Crunchbase News
Biotech company Amplyx Pharmaceuticals increases its Series C to more than $90 million, aimed at advancing two therapies toward clinical development.
Mark Terry
May 19, 2020
BioSpace
San Diego-based Amplyx Pharmaceuticals closed a Series C extension round worth $53 million, bringing the Series C round total to more than $90 million.
FinSMEs
May 19, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amirah Al Idrus
May 19, 2020
FierceBiotech
Eight months after picking up an antibody program from Novartis, Amplyx Pharmaceuticals topped up its coffers to push it through phase 2. Pfizer and Adage Capital Management got in its series C extension, bringing the round's total to $93 million.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.